CPTC-AXL-1 (CAB080167)

Uniprot ID: P30530

Protein name: UFO_HUMAN


Full name: Tyrosine-protein kinase receptor UFO

Tissue specificity: Highly expressed in metastatic colon tumors. Expressed in primary colon tumors. Weakly expressed in normal colon tissue. **Function**: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, AXL binds and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. (Microbial infection) Acts as a receptor for lassa virus and lymphocytic choriomeningitis virus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope. (Microbial infection) Promotes Zika virus entry in glial cells, Sertoli cells and astrocytes (PubMed:28076778, PubMed:28076778). Interferon signaling inhibition occurs via an SOCS1-dependent mechanism (PubMed:28076778). Interferon signaling inhibition occurs via an SOCS1-dependent mechanism (PubMed:280797210).


Cell membrane (*experimental evidence*) (Topo: Single-pass type I membrane protein (*experimental evidence*)) **Protein existence**: Experimental evidence at protein level

Comment:

Immunohistochemistry




Immunofluorescence



IHC protocol:	HIER pH6, Dilution 1:250	
IHC test staining:	Positivity in plasma.	
Literature conformance:	Not consistent with gene/protein characterization data	
Literature significance:		
RNA similarity:	Very low consistency between antibody staining and RNA expression data	
RNA tissue specificity:	Low tissue specificity	
RNA tissue distribution:	Detected in all	
IHC Sibling similarity:	Other antibody shows dissimilar IHC staining pattern	
IHC fail comment:	ANTIBODY FAILED: Not consistent with RNA	

IF Overlay:	antibody (green), anti-tubulin (red) and DAPI (blue)
IF main location:	
IF additional location:	
IF approved for publication on HPA:	No
IF in THP-1:	Negative
IF in U-2 OS:	Negative

Western blot



WB Size markers (kDa):	250, 130, 100, 70, 55, 35, 25, 15, 10	
WB Lanes:	Marker (1), RT4 (2), U-251 MG (3), Plasma (4), Liver (5), Tonsil (6)	
WB Target weight (kDa):	69, 97, 98	
WB Validation:	Supported (Band of predicted size in kDa (+/-20%) with additional bands present.)	